Crucell Awarded $230 Million in Vaccine Contracts
Posted on: Friday, 1 December 2006, 06:00 CST
Dutch biotechnology company Crucell has been awarded contracts totaling over $230 million for its Quinvaxem and Hepavax-Gene pediatric vaccines.
The contracts cover the next three years until 2009, with the awarded amount growing over those three years.
Following a WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.
Quinvaxem, a fully-liquid pentavalent vaccine for children, was co-developed with Novartis. The vaccine combines antigens for protection against five important childhood diseases including diphtheria, tetanus, whooping cough, hepatitis B and haemophilus influenzae type b, one of the leading causes of bacterial meningitis and pneumonia in children.
The Hepavax-Gene, recombinant hepatitis B vaccine, is one of the WHO's pre-qualified vaccines for active immunization against the hepatitis B virus. Young children infected with hepatitis B are the most likely to develop chronic infections.
Source: Datamonitor
Related Articles
- Vaccinating Children Could Be Effective At Helping Control Spread Of Influenza
- Children’s Vaccine Found To Cut Meningitis Rates
- Federal Advisory Committee Votes to Include Newly Licensed Pentacel(R) Vaccine in Vaccines for Children Program
- Hepatitis C Virus DNA Vaccine Shows Safety When Delivered By Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
- Merck Recalls Children's Vaccine
- Partnership for Cleveland Children's Vaccinations Announced
- Lawmakers Approve Mercury Measure; Substance Largely Banned From Children's Vaccines
- Meningitis Among Targets of New Children's Vaccine
- UK to vaccinate children against meningitis disease
- Hepatitis C in Children
 |
 |
User Comments (0)
RSS Feeds